← boardnext 2027-07-01
VKTX
Viking Therapeutics, Inc.distress 5/10 · elevated risk$36.33-3%today-14% from 52w high
Metabolic / Obesity 1
Lead: Weight Loss · target GLP-1/GIP · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$118M
Runway
0.3 yrs
Shares 1y
+3%
Price & events
+6.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-0.1%
1W
+4.4%
1M
+10.8%
3M
+12.8%
6M
+8.8%
1Y
-29.5%
2Y
+529.6%
5Y
+526.4%
All
Overview
- Market Cap
- $4.22B
- Volume
- 135.35K
- 52 Week Range
- $23.09 – $42.13
- Total Shares
- 116.11M
- Float Shares
- 113.28M
- Short %
- 21.40%
- % Held by Insiders
- 2.79%
- % Held by Institutions
- 64.47%
- RVOL
- 0.05x
- Beta
- 0.66
Pipeline stages · 1 programs
VK2735
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
Catalyst news & presentations · 2
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-03-10partnershipVK2735 · Manufacturing and supply agreement with CordenPharma for API and drug productSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $93 (+155% upside) · 19 analysts
- 2026-05-28Lake StreetBuy
- 2026-05-01BTIGBuy
- 2026-04-30Cantor FitzgeraldOverweight
- 2026-03-23HC Wainwright & Co.Buy
- 2025-11-12Canaccord GenuityBuy
- 2025-10-29Canaccord GenuityBuy
Competitors — GLP-1/GIP
Recent news
- 2026-07-23VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
- 2026-07-23Viking Therapeutics adds Dorothy Gemmell to board of directors - Investing.com
- 2026-07-23Dorothy Gemmell Joins Viking Board After 25+ Years in Healthcare - Stock Titan
- 2026-07-23Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors - PR Newswire
- 2026-07-23Viking Therapeutics to report Q2 2026 results on July 29 - scanx.trade
- 2026-07-22Viking Therapeutics’ Q2 results arrive after markets close - Stock Titan
- 2026-07-22Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 - Yahoo Finance Australia
- 2026-07-22VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.